




PHARMACEUTICAL 2023

Chemomab Therapeutics Ltd.
Rank 165 of 446





PHARMACEUTICAL 2023

Chemomab Therapeutics Ltd.
Rank 165 of 446

The relative strengths and weaknesses of Chemomab Therapeutics Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Chemomab Therapeutics Ltd. is the variable Net Income, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 139%, being 96% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	41,736
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,749
Liabilities, Non-Current	91
Other Assets	960
Other Compr. Net Income	0
Other Expenses	-534
Other Liabilities	0
Other Net Income	353
Other Revenues	0
Property and Equipment	367
Research and Development	16,977
Selling, General and Administrative Expense	11,556

Output Variable	Value in 1000 USD
Assets	43,063
Liabilities	6,840
Expenses	27,999
Revenues	0
Stockholders Equity	36,223
Net Income	-27,646
Comprehensive Net Income	-27,646
Economic Capital Ratio	139%